Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Authors:

Abstract
No abstract available
Funding Information
  • Eisai Inc

This publication has 36 references indexed in Scilit: